JPH0216284B2 - - Google Patents

Info

Publication number
JPH0216284B2
JPH0216284B2 JP56150082A JP15008281A JPH0216284B2 JP H0216284 B2 JPH0216284 B2 JP H0216284B2 JP 56150082 A JP56150082 A JP 56150082A JP 15008281 A JP15008281 A JP 15008281A JP H0216284 B2 JPH0216284 B2 JP H0216284B2
Authority
JP
Japan
Prior art keywords
threo
dops
disease
dopa
freezing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP56150082A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5852219A (ja
Inventor
Hirotaro Narabayashi
Tomoyoshi Kondo
Akira Hayashi
Tomokazu Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SUMITOMO SEIYAKU KK
Original Assignee
SUMITOMO SEIYAKU KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SUMITOMO SEIYAKU KK filed Critical SUMITOMO SEIYAKU KK
Priority to JP56150082A priority Critical patent/JPS5852219A/ja
Priority to US06/415,907 priority patent/US4497826A/en
Priority to NZ201864A priority patent/NZ201864A/en
Priority to CA000411281A priority patent/CA1184501A/en
Priority to NLAANVRAGE8203594,A priority patent/NL189648C/xx
Priority to CH5515/82A priority patent/CH650926A5/de
Priority to FR8215806A priority patent/FR2513117B1/fr
Priority to AU88578/82A priority patent/AU556542B2/en
Priority to MX888082A priority patent/MX155121A/es
Priority to BE0/209060A priority patent/BE894451A/fr
Priority to IT8268118A priority patent/IT1212668B/it
Priority to SE8205404A priority patent/SE462781B/sv
Priority to DE19823235093 priority patent/DE3235093A1/de
Priority to GB08227076A priority patent/GB2106388B/en
Publication of JPS5852219A publication Critical patent/JPS5852219A/ja
Priority to AU67501/87A priority patent/AU575267B2/en
Publication of JPH0216284B2 publication Critical patent/JPH0216284B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP56150082A 1981-09-22 1981-09-22 パ−キンソン病治療剤 Granted JPS5852219A (ja)

Priority Applications (15)

Application Number Priority Date Filing Date Title
JP56150082A JPS5852219A (ja) 1981-09-22 1981-09-22 パ−キンソン病治療剤
US06/415,907 US4497826A (en) 1981-09-22 1982-09-08 Antiparkinsonian agent
NZ201864A NZ201864A (en) 1981-09-22 1982-09-09 An antiparkinsonian composition
CA000411281A CA1184501A (en) 1981-09-22 1982-09-13 Antiparkinsonian agent
NLAANVRAGE8203594,A NL189648C (nl) 1981-09-22 1982-09-16 Farmaceutisch preparaat met werking op het centrale zenuwstelsel op basis van 3-(3,4-dihydroxyfenyl)-serine en een decarboxylase-remmer.
CH5515/82A CH650926A5 (de) 1981-09-22 1982-09-17 Antiparkinson-mittel.
FR8215806A FR2513117B1 (fr) 1981-09-22 1982-09-20 Agent contre la maladie de parkinson, comprenant de la threo-3, 4-dihydroxyphenylserine et un inhibiteur de decarboxylase
AU88578/82A AU556542B2 (en) 1981-09-22 1982-09-21 Dihydroxyphenylserine and decarboxylase inhibitor
MX888082A MX155121A (es) 1981-09-22 1982-09-21 Procedimiento para preparar una composicion antiparkinsoniana a base de treo-3,4-dihidroxifenilserina y un inhibidor de descarboxilasa
BE0/209060A BE894451A (fr) 1981-09-22 1982-09-21 Agent antiparkinsonien
IT8268118A IT1212668B (it) 1981-09-22 1982-09-21 Agente antiparkinsoniano a base di treo 3 4 diidrossifenilserina
SE8205404A SE462781B (sv) 1981-09-22 1982-09-21 Medel mot parkinsonism omfattande l-treo-3,4-dihydroxifenylserin och en dekarboxylas inhibitor
DE19823235093 DE3235093A1 (de) 1981-09-22 1982-09-22 Antiparkinsonmittel
GB08227076A GB2106388B (en) 1981-09-22 1982-09-22 Antiparkinsonian agent
AU67501/87A AU575267B2 (en) 1981-09-22 1987-01-12 Parkinsons disease treatments using threo-3-4hydroxyphenyl- serine and a decarboxylase inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56150082A JPS5852219A (ja) 1981-09-22 1981-09-22 パ−キンソン病治療剤

Publications (2)

Publication Number Publication Date
JPS5852219A JPS5852219A (ja) 1983-03-28
JPH0216284B2 true JPH0216284B2 (enExample) 1990-04-16

Family

ID=15489114

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56150082A Granted JPS5852219A (ja) 1981-09-22 1981-09-22 パ−キンソン病治療剤

Country Status (13)

Country Link
US (1) US4497826A (enExample)
JP (1) JPS5852219A (enExample)
AU (2) AU556542B2 (enExample)
BE (1) BE894451A (enExample)
CA (1) CA1184501A (enExample)
CH (1) CH650926A5 (enExample)
DE (1) DE3235093A1 (enExample)
FR (1) FR2513117B1 (enExample)
GB (1) GB2106388B (enExample)
IT (1) IT1212668B (enExample)
NL (1) NL189648C (enExample)
NZ (1) NZ201864A (enExample)
SE (1) SE462781B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6067420A (ja) * 1983-09-22 1985-04-17 Sumitomo Chem Co Ltd 精神運動興奮抑制剤
AU575849B2 (en) * 1983-09-22 1988-08-11 Sumitomo Chemical Company, Limited Pharmaceutical composition and method for treatment of psychomotor excitement
NZ209514A (en) * 1983-09-22 1988-03-30 Sumitomo Chemical Co Pharmaceutical compositions containing erythro-3,4-dihydroxyphenylserine and a decarboxylase inhibitor
JPS60132935A (ja) * 1983-12-20 1985-07-16 Sumitomo Chem Co Ltd フエニルセリン誘導体及びその製造方法
JPS6185318A (ja) * 1984-10-04 1986-04-30 Sumitomo Seiyaku Kk 利尿薬
ZA889189B (en) * 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4863962A (en) * 1988-03-02 1989-09-05 Fidia-Georgetown Institute For The Neurosciences D-DOPA, pharmaceutically acceptable salts thereof, and methods of treating Parkinson's disease
PT99864B (pt) * 1990-12-21 1999-06-30 Schering Ag Processo para a preparacao de novas composicoes farmaceuticas contendo antagonistas de receptor de quisqualato
DE4101873C2 (de) 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
JP3559572B2 (ja) 1993-01-29 2004-09-02 住友製薬株式会社 急性痛および慢性痛用鎮痛剤
JP3764179B2 (ja) * 1994-07-05 2006-04-05 克寛 西野 運動・意識または言語障害の機能改善剤
US5668114A (en) * 1996-05-08 1997-09-16 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating hypertension
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
US20070010584A1 (en) * 2003-09-04 2007-01-11 Peroutka Stephen J Compositions and methods for orthostatic intolerance
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US7786126B2 (en) * 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
ES2571730T3 (es) * 2006-06-28 2016-05-26 Lundbeck Na Ltd Composiciones farmacéuticas que comprenden droxidopa
AU2008226541B2 (en) * 2007-03-09 2013-05-09 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
EP2167066B1 (en) * 2007-05-07 2013-06-26 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of attention deficit disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
JPWO2011001976A1 (ja) 2009-07-01 2012-12-13 大日本住友製薬株式会社 スレオ−３−（３，４−ジヒドロキシフェニル）−ｌ−セリンの製造法
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL34687A (en) * 1969-06-18 1973-07-30 Merck & Co Inc Compounds of a-hydrazino-b-acid (3,4-dihydroxyphenyl) -a-converted propionate
US3658968A (en) * 1970-06-11 1972-04-25 Merck & Co Inc Composition and method of treatment
DE2305209A1 (de) * 1972-02-14 1973-08-23 Hoffmann La Roche Pharmazeutisches praeparat
AU6889274A (en) * 1973-05-17 1975-11-20 Astra Laekemedel Ab Treatment of neurological disorders
CH580059A5 (enExample) * 1973-08-22 1976-09-30 Hoffmann La Roche
US3920728A (en) * 1973-08-22 1975-11-18 Hoffmann La Roche Separation and resolution of isomeric forms of 3-(3,4-dihydroxy-phenyl)-serine
JPS52125630A (en) * 1976-04-14 1977-10-21 Kyowa Hakko Kogyo Co Ltd Antiperkinson drugs containing l-threo-3,4-dihydroxyphenylserine
JPS56104815A (en) * 1980-01-23 1981-08-20 Sumitomo Chem Co Ltd Remedy for peripheral orthostatic hypotension

Also Published As

Publication number Publication date
CA1184501A (en) 1985-03-26
IT1212668B (it) 1989-11-30
JPS5852219A (ja) 1983-03-28
SE8205404L (sv) 1983-03-23
SE8205404D0 (sv) 1982-09-21
NZ201864A (en) 1985-12-13
US4497826A (en) 1985-02-05
NL8203594A (nl) 1983-04-18
SE462781B (sv) 1990-09-03
FR2513117B1 (fr) 1986-01-24
DE3235093C2 (enExample) 1988-12-29
DE3235093A1 (de) 1983-04-07
CH650926A5 (de) 1985-08-30
GB2106388B (en) 1986-03-26
AU8857882A (en) 1983-03-31
NL189648C (nl) 1993-06-16
FR2513117A1 (fr) 1983-03-25
NL189648B (nl) 1993-01-18
AU575267B2 (en) 1988-07-21
GB2106388A (en) 1983-04-13
AU6750187A (en) 1987-04-16
IT8268118A0 (it) 1982-09-21
BE894451A (fr) 1983-03-21
AU556542B2 (en) 1986-11-06

Similar Documents

Publication Publication Date Title
JPH0216284B2 (enExample)
US20050026977A1 (en) Zonisamide use in eating disorders
RS20050392A (sr) Farmaceutski preparat sa beta-3- adrenoceptor-agonistom i reuptake-inhibitorom serotonina i/ili norepinefrina
US11590107B2 (en) Methods for treating neurological disorders with α1A-AR partial agonists
US4438119A (en) Method for alleviation of extrapyramidal motor disorders
JP2003523405A (ja) 睡眠改善のための方法および組成物
JPH05503102A (ja) 喘息の治療のための光学的純粋ｒ（−）アルブテロール
US4690949A (en) Therapeutic drug for dementia
JPH09323927A (ja) 慢性閉塞性動脈硬化症の治療のためのカルニチン誘導体含有薬剤
JP2002541198A (ja) 失禁の治療法
JPS6067420A (ja) 精神運動興奮抑制剤
JPS6133803B2 (enExample)
AU2019221886B2 (en) Therapeutic agents for treating restless legs syndrome
Fahn Atypical tremors, rare tremors and unclassified tremors
US20100168191A1 (en) Pharmaceutical formulation comprising pramipexole
JP2001526217A (ja) 血管性頭痛に対する局所麻酔薬の新規な使用
JP2005525377A (ja) デスメチルセレジリンの投与による末梢神経障害の予防および処置のための方法
JPH0233689B2 (enExample)
US20030191191A1 (en) Methods for preventing and treating peripheral neuropathy by administering desmethylselegiline delivery compositions
WO2025163129A1 (en) Acetyl-leucine for treating parkinson´s disease
CN118946348A (zh) 用于治疗帕金森病的药物组合物
HK40036165A (en) Acetyl-leucine for use in treating restless leg syndrome
MXPA05004935A (es) Tratamiento de desordenes gastrointestinales con duloxetina.
WO1998026778A1 (en) Remedies/preventives for abnormal motions accompanying disorders in extrapyramidal system
WO1993011765A1 (en) Novel use of (+)-2-nitroxyethyl apovincaminate